Google’s president and chief investment officer Ruth Porat made bold predictions about AI’s potential to solve humanity’s biggest challenges at the Fortune Global Forum. She argued the technology represents far more than chatbots, pointing to breakthroughs in healthcare and the urgent need for infra
Advanced AI algorithms are now being deployed in mammography centers nationwide, offering unprecedented breast cancer risk prediction capabilities. These tools can detect subtle patterns invisible to human radiologists and are showing significant improvements in early cancer detection rates.
Medical facilities across the United States are implementing a groundbreaking approach to breast cancer screening, with artificial intelligence now capable of assessing women’s short-term breast cancer risk through routine mammograms. According to reports, the FDA-authorized Clairity Breast tool analyzes mammogram features invisible to human radiologists to generate five-year risk scores, marking a significant departure from traditional genetic and family history-based assessments.
A groundbreaking blood test has demonstrated remarkable success in detecting over 50 cancer types in major clinical trials. The test identified more than half of cancers at early stages when they’re most treatable, according to study results presented at a leading medical conference.
A revolutionary blood test designed to detect more than 50 types of cancer has delivered highly promising results in one of the largest interventional screening trials conducted to date, according to reports presented at the European Society for Medical Oncology Congress 2025 in Berlin. The PATHFINDER 2 study of the Galleri multi-cancer early detection (MCED) test reportedly showed a more than seven-fold increase in cancer detection rates when used alongside standard recommended screenings.
Circle Pharma will present promising preclinical data on its first-in-class oral macrocyclic cyclin D1-selective inhibitors at the upcoming AACR-NCI-EORTC conference. The company’s innovative approach targets cyclin D1-driven cancers through selective disruption of the cyclin D1-Rb interaction.
Circle Pharma, a clinical-stage biopharmaceutical company focused on developing targeted macrocycle therapeutics, has announced an upcoming poster presentation highlighting the significant anti-tumor potential of cyclin D1 RxL inhibition. The presentation will occur at the prestigious AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025.
AstraZeneca boosts Virginia plant investment to $4.5B, creating 3,600 jobs Historic investment fuels US drug manufacturing push AstraZeneca has significantly…
